MICA/B Antibody (D-8): sc-271535

MICA/B Antibody (D-8) is a mouse monoclonal IgG2a antibody that detects MICA in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). MICA is a stress-induced antigen closely related to major histocompatibility complex (MHC) class I molecules and is predominantly expressed on the surface of epithelial cells, particularly in the context of tumors. MICA on the cell surface serves as a signal of cellular distress, alerting the immune system to potential threats. MICA is highly glycosylated and is expressed independently of conventional class I peptide ligands or β-2-Microglobulin, which allows stable presentation on the cell surface during conditions of stress, such as heat shock or cellular proliferation. MICA engagement with Vδ1 γδ T cells in the intestinal epithelium underscores MICA′s importance in mediating immune responses, particularly in epithelial tumors, where MICA may play a pivotal role in the recognition and elimination of stressed or malignant cells. Anti-MICA/B antibody (D-8) is an essential tool for researchers investigating the immune response in cancer and other diseases characterized by cellular stress.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MICA/B Antibody (D-8) References:

1. Hepatitis B surface antigen inhibits MICA and MICB expression via induction of cellular miRNAs in hepatocellular carcinoma cells.  |  Wu, J., et al. 2014. Carcinogenesis. 35: 155-63. PMID: 23917076
2. A hypoxia-induced decrease of either MICA/B or Hsp70 on the membrane of tumor cells mediates immune escape from NK cells.  |  Schilling, D., et al. 2015. Cell Stress Chaperones. 20: 139-47. PMID: 25103413
3. MHC class I chain-related protein A and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue.  |  Ghadially, H., et al. 2017. Br J Cancer. 116: 1208-1217. PMID: 28334733
4. High-Throughput MICA/B Genotyping of Over Two Million Samples: Workflow and Allele Frequencies.  |  Klussmeier, A., et al. 2020. Front Immunol. 11: 314. PMID: 32153595
5. MICA/B antibody induces macrophage-mediated immunity against acute myeloid leukemia.  |  Alves da Silva, PH., et al. 2022. Blood. 139: 205-216. PMID: 34359073
6. MICA/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma.  |  Oliviero, B., et al. 2022. Oncoimmunology. 11: 2035919. PMID: 35223192
7. Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.  |  Bléry, M., et al. 2021. Open Res Eur. 1: 107. PMID: 35967081
8. Downregulation of MICA/B tumor surface expressions and augmented soluble MICA serum levels correlate with disease stage in breast cancer.  |  Kshersagar, J., et al. 2022. Breast Dis. 41: 471-480. PMID: 36641654
9. A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors.  |  Goulding, J., et al. 2023. Med. 4: 457-477.e8. PMID: 37172578
10. A novel MICA/B-targeted chimeric antigen receptor augments the cytotoxicity of NK cells against tumor cells.  |  Guo, C., et al. 2024. Biochem Biophys Res Commun. 710: 149918. PMID: 38598902

The preferred MICA antibody is MICA Antibody (2C10): sc-23870.